Identifying candidates with promising ADME and pharmacokinetics properties during the discovery phase of drug development lays the groundwork for future clinical trials and regulatory approval. However, translating a long-term study into a successful outcome requires reliable, qualified measurements at a clinical scale.
Q2 Solutions’ global bioanalytical services network brings substantial expertise in biomarker assays and cell-based bioanalytical assays that target multi-domain proteins, antibodies, oligonucleotides, antibody-drug conjugates, and peptides.
Specific strengths include:
Supporting data from high-volume, regulated clinical studies
Solutions for your large molecule bioanalysis and the successful outcome you seek
Specifica, a Q2 Solutions company, is applying its proven platform for antibody discovery to generate recombinant monoclonal antibody reagents. Our in vitro display approach eliminates the need for...
ImmunXperts, a Q2 Solutions company, provides functional insights into immune-mediated adverse events. We provide in silico and in vitro methods, using T-cell activation and proliferation as a...
If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...